B cells and cancer: To B or not to B?


Journal

The Journal of experimental medicine
ISSN: 1540-9538
Titre abrégé: J Exp Med
Pays: United States
ID NLM: 2985109R

Informations de publication

Date de publication:
04 01 2021
Historique:
received: 19 07 2020
revised: 02 09 2020
accepted: 17 09 2020
entrez: 18 2 2021
pubmed: 19 2 2021
medline: 31 8 2021
Statut: ppublish

Résumé

Whereas T cells have been considered the major immune cells of the tumor microenvironment able to induce tumor regression and control cancer clinical outcome, a burst of recent publications pointed to the fact that B cells may also play a prominent role. Activated in germinal centers of tertiary lymphoid structures, B cells can directly present tumor-associated antigens to T cells or produce antibodies that increase antigen presentation to T cells or kill tumor cells, resulting in a beneficial clinical impact. Immune complexes can also increase inflammation, angiogenesis, and immunosuppression via macrophage and complement activation, resulting in deleterious impact.

Identifiants

pubmed: 33601413
pii: 211614
doi: 10.1084/jem.20200851
pmc: PMC7754675
pii:
doi:

Substances chimiques

Antigens, Neoplasm 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2020 Fridman et al.

Déclaration de conflit d'intérêts

Disclosures: T.W.-W. Chen reported personal fees from Novartis, Roche, Eli Lilly, Daiichi Sankyio, and Eisai outside the submitted work. No other disclosures were reported.

Références

Nature. 2020 Jan;577(7791):556-560
pubmed: 31942077
Clin Cancer Res. 2014 Jul 15;20(14):3818-29
pubmed: 24916698
Cancer Immunol Res. 2019 Jul;7(7):1091-1105
pubmed: 31164356
Gynecol Oncol. 2016 Oct;143(1):120-127
pubmed: 27470997
Sci Rep. 2019 Dec 27;9(1):19997
pubmed: 31882709
J Clin Oncol. 2008 Sep 20;26(27):4410-7
pubmed: 18802153
Nat Rev Immunol. 2015 Jul;15(7):441-51
pubmed: 26065586
Oncoimmunology. 2018 Jun 11;7(8):e1465165
pubmed: 30221062
Nat Immunol. 2017 Feb 15;18(3):255-262
pubmed: 28198830
Mod Pathol. 2016 Apr;29(4):347-58
pubmed: 26867783
Cancer Cell. 2005 May;7(5):411-23
pubmed: 15894262
Cancer Res. 2011 Aug 15;71(16):5412-22
pubmed: 21708957
Genome Med. 2019 May 28;11(1):36
pubmed: 31138334
Nat Biotechnol. 2017 Oct 11;35(10):908-911
pubmed: 29020005
Scand J Immunol. 2020 Feb;91(2):e12830
pubmed: 31823416
Nat Commun. 2019 Sep 13;10(1):4186
pubmed: 31519915
Front Immunol. 2016 Oct 03;7:401
pubmed: 27752256
Br J Cancer. 2019 Jan;120(1):3-5
pubmed: 30413824
Hum Pathol. 2016 Aug;54:157-64
pubmed: 27107457
Nature. 2017 Nov 16;551(7680):340-345
pubmed: 29144460
Clin Cancer Res. 2018 Dec 15;24(24):6125-6135
pubmed: 30049748
Science. 2015 Apr 3;348(6230):124-8
pubmed: 25765070
Cancer Immunol Res. 2017 Oct;5(10):898-907
pubmed: 28848053
Oncoimmunology. 2020 Apr 7;9(1):1747339
pubmed: 32313726
Nat Med. 1998 May;4(5):627-30
pubmed: 9585241
Nat Rev Cancer. 2019 Jun;19(6):307-325
pubmed: 31092904
Breast Cancer Res Treat. 2020 Apr;180(2):369-377
pubmed: 32034580
Science. 2006 Sep 29;313(5795):1960-4
pubmed: 17008531
Cancer Immunol Res. 2015 Dec;3(12):1325-32
pubmed: 26216416
BMC Biotechnol. 2007 Oct 18;7:70
pubmed: 17945015
Cancer Res. 2014 Feb 1;74(3):705-15
pubmed: 24366885
Nature. 2020 Jan;577(7791):549-555
pubmed: 31942075
Clin Cancer Res. 2013 Nov 1;19(21):5994-6005
pubmed: 24056784
Heliyon. 2016 Aug 16;2(8):e00143
pubmed: 27579449
Immunity. 2006 Oct;25(4):643-54
pubmed: 17045819
Cancer Cell. 2018 Oct 8;34(4):561-578.e6
pubmed: 30300579
Cancer Immunol Immunother. 2000 Jan;48(10):541-9
pubmed: 10630306
Clin Cancer Res. 2014 Apr 15;20(8):2147-58
pubmed: 24523438
J Natl Cancer Inst. 2013 Sep 18;105(18):1385-93
pubmed: 23940286
J Immunol. 2016 Sep 1;197(5):1957-67
pubmed: 27474071
J Natl Cancer Inst. 2016 Jun 22;108(11):
pubmed: 27335052
Nat Rev Immunol. 2014 Jul;14(7):447-62
pubmed: 24948366
Clin Cancer Res. 2010 Jun 15;16(12):3226-31
pubmed: 20515868
Cancer Res. 2006 Aug 1;66(15):7741-7
pubmed: 16885377
Nat Immunol. 2007 Sep;8(9):992-1000
pubmed: 17660822
Cancer Immunol Immunother. 2007 Sep;56(9):1459-69
pubmed: 17279413
Nat Rev Clin Oncol. 2017 Dec;14(12):717-734
pubmed: 28741618
Clin Cancer Res. 2017 Jan 1;23(1):250-262
pubmed: 27354470
Breast Cancer. 2019 Mar;26(2):180-189
pubmed: 30244409
Cell. 2020 Mar 19;180(6):1081-1097.e24
pubmed: 32142650
Front Immunol. 2017 Feb 03;8:45
pubmed: 28217126
J Immunol. 1978 Jul;121(1):359-62
pubmed: 307580
Breast Cancer Res Treat. 2012 Apr;132(2):545-53
pubmed: 21671016
Clin Cancer Res. 2016 Jun 15;22(12):3005-15
pubmed: 26763251
J Hepatol. 2019 Jan;70(1):58-65
pubmed: 30213589
Oncoimmunology. 2015 Jun 5;5(1):e1057387
pubmed: 26942066
Front Immunol. 2018 May 30;9:1209
pubmed: 29899747
Acta Oncol. 2007;46(3):316-23
pubmed: 17450466
Annu Rev Immunol. 2015;33:715-45
pubmed: 25861980
Cancer Cell. 2014 Jun 16;25(6):809-821
pubmed: 24909985
Cell. 2018 Oct 4;175(2):442-457.e23
pubmed: 30290143
Cancer Res. 2015 Dec 1;75(23):5008-13
pubmed: 26573795
Aging (Albany NY). 2020 Feb 22;12(4):3451-3472
pubmed: 32087064
JCI Insight. 2019 Aug 13;5:
pubmed: 31408436
J Immunol. 2009 Jan 1;182(1):5-7
pubmed: 19109126
Nature. 2020 Jan;577(7791):561-565
pubmed: 31942071
Front Immunol. 2016 Nov 08;7:477
pubmed: 27877173
Immunity. 1995 Jul;3(1):21-6
pubmed: 7621075
Nat Rev Cancer. 2012 Mar 15;12(4):298-306
pubmed: 22419253
Immunity. 2020 Jan 14;52(1):183-199.e9
pubmed: 31924475
Curr Opin Immunol. 2007 Apr;19(2):209-16
pubmed: 17276050
Immunity. 2013 Oct 17;39(4):782-95
pubmed: 24138885
Nat Rev Cancer. 2019 Dec;19(12):698-715
pubmed: 31666715
Nat Immunol. 2015 Dec;16(12):1235-44
pubmed: 26502405
Sci Rep. 2019 Sep 11;9(1):13083
pubmed: 31511630
JCI Insight. 2017 Jun 2;2(11):
pubmed: 28570278
Cell Rep. 2016 May 17;15(7):1505-1513
pubmed: 27160908
Cancer Res. 2018 Mar 1;78(5):1308-1320
pubmed: 29279354
J Immunol. 2002 Aug 15;169(4):1829-36
pubmed: 12165506
Mol Immunol. 2014 Mar;58(1):56-65
pubmed: 24309484
Oncoimmunology. 2017 Dec 18;7(2):e1378844
pubmed: 29416939
Gut. 2017 Feb;66(2):342-351
pubmed: 26669617
Cancer Sci. 2019 Jun;110(6):1853-1862
pubmed: 30997706
Clin Cancer Res. 2020 Aug 15;26(16):4381-4389
pubmed: 32269054
J Immunol. 2010 Apr 1;184(7):4006-16
pubmed: 20194720
Front Oncol. 2018 Jul 09;8:256
pubmed: 30038899
Nat Rev Clin Oncol. 2020 Jul;17(7):393-394
pubmed: 32372036
Int J Cancer. 2003 Jan 1;103(1):97-100
pubmed: 12455059
J Exp Med. 2002 Jun 17;195(12):1653-9
pubmed: 12070293
Am J Respir Crit Care Med. 2014 Apr 1;189(7):832-44
pubmed: 24484236
J Exp Med. 1996 Dec 1;184(6):2385-92
pubmed: 8976192
Int J Cancer. 2008 Nov 15;123(10):2354-61
pubmed: 18729197
Int J Oncol. 2020 Jul;57(1):171-182
pubmed: 32319601
Cancer Metastasis Rev. 2010 Jun;29(2):309-16
pubmed: 20405169
Br J Cancer. 2013 Nov 12;109(10):2665-74
pubmed: 24136146
Blood. 2006 Oct 15;108(8):2712-9
pubmed: 16809616
Int J Cancer. 2005 Nov 20;117(4):574-86
pubmed: 15912532
Trends Immunol. 2016 Dec;37(12):844-854
pubmed: 27793570
PLoS One. 2009 Jul 29;4(7):e6412
pubmed: 19641607
Clin Exp Immunol. 2020 Feb;199(2):172-181
pubmed: 31652350
Science. 2015 Apr 3;348(6230):56-61
pubmed: 25838373
Clin Cancer Res. 2012 Jun 15;18(12):3281-92
pubmed: 22553348
Br J Cancer. 2015 May 26;112(11):1782-90
pubmed: 25942397
Cancer Res. 2018 Jan 1;78(1):143-156
pubmed: 29118090

Auteurs

Wolf Herman Fridman (WH)

Centre de Recherche des Cordeliers, Sorbonne Université, Institut national de la santé et de la recherche médicale, Université de Paris, Paris, France.

Florent Petitprez (F)

Programme Cartes d'Identité des Tumeurs, Ligue Nationale contre le Cancer, Paris, France.

Maxime Meylan (M)

Centre de Recherche des Cordeliers, Sorbonne Université, Institut national de la santé et de la recherche médicale, Université de Paris, Paris, France.

Tom Wei-Wu Chen (TW)

Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.

Cheng-Ming Sun (CM)

Centre de Recherche des Cordeliers, Sorbonne Université, Institut national de la santé et de la recherche médicale, Université de Paris, Paris, France.

Lubka T Roumenina (LT)

Centre de Recherche des Cordeliers, Sorbonne Université, Institut national de la santé et de la recherche médicale, Université de Paris, Paris, France.

Catherine Sautès-Fridman (C)

Centre de Recherche des Cordeliers, Sorbonne Université, Institut national de la santé et de la recherche médicale, Université de Paris, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH